Jazz Pharmaceuticals Announces Participation at Cowen 41st Annual Healthcare Conference
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced participation in the Cowen 41st Annual Healthcare Conference, with CEO Bruce Cozadd presenting on March 2, 2021, at 12:50 p.m. EST. The webcast will cover a business and financial update and can be accessed through their website.
Archived audio of the presentation will be available for at least a week following the event. Jazz Pharmaceuticals focuses on developing life-changing medicines in neuroscience and oncology, serving patients in over 90 countries.
- Participation in a major healthcare conference, potentially enhancing visibility among investors.
- CEO will provide a business and financial update, which could positively influence investor sentiment.
- None.
DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Cowen 41st Annual Healthcare conference.
Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update on Tuesday, March 2, 2021, at 12:50 p.m. EST / 5:50 p.m. GMT.
A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of each presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
An archive of each webcast will be available for at least one week following each presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
Jazz Pharmaceuticals Contacts: | |
Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations U.S. +1 561 306 4035 | Media: Jacqueline Kirby Vice President, Corporate Affairs & Government Relations Ireland +353 1 697 2141 U.S. +1 215 867 4910 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-participation-at-cowen-41st-annual-healthcare-conference-301232868.html
SOURCE Jazz Pharmaceuticals plc
